Centessa Pharmaceuticals — Investor Presentation (June 2023)
23 slides from Centessa Pharmaceuticals's investor presentation, Jun 9, 2023
Slide 1: Corporate Overview June 2023
Corporate Overview JUNE 2023 Asset-Centric. Patient-Centric.
Slide 2: Disclaimer and forward-looking statements
This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv
Slide 3: Discovering and developing medicines transformational for patients
Discovering and developing medicines that are transformational for patients Multiple potential blockbuster assets Cash runway into 2026 enables clinical readouts across portfolio World-class R&D team 3Note: $346.2 million in cash, cash equivalents and short-term investments as of March 31, 2023.
Slide 4: We are a transformational pharmaceutical company fueling an innovative pipeline
DIFFERENTIATION We are a transformational pharmaceutical company fueling an innovative pipeline 4 Lead Assets Disease Estimated Market Size* SerpinPC Hemophilia B $2B+1 PD-L1xCD47 LockBody® (LB101) Solid Tumors $10B1 PD-L1xCD3 LockBody® Program Solid Tumors $10B1 ORX750 Narcolepsy (NT1) and other sl
Slide 5: Cash runway into 2026 enables clinical readouts across pipeline
5 CASH RUNWAY INTO 2026 ENABLES CLINICAL READOUTS ACROSS PIPELINE Centessa has multiple early-stage programs, including MGX292 and discovery-stage programs not reflected on this slide. INNOVATIVE PIPELINE Potential first-in-class/ best-in-class medicines for patients ASSET DISEASE MECHANISM PRE- CLI
Slide 6: Leadership: team with deep R&D experience and focused on execution
LEADERSHIP Team with deep R&D experience and focused on execution 6 DAVID CHAO PhD Chief Administrative Officer TIA BUSH Chief Quality Officer SAURABH SAHA MD PhD Chief Executive Officer ANTOINE YVER MD MSc EVP & Chairman of Development DAVID GRAINGER PhD Chief Innovation Officer IQBAL HUSSAIN Gener
Slide 7: SerpinPC in Hemophilia
SerpinPC in Hemophilia YK CENTESSA
Slide 8: SerpinPC: Novel, subcutaneously administered biologic inhibitor of APC
SerpinPC: Novel, subcutaneously administered biologic inhibitor of APC 8 Novel MoA; Showed significant reduction in bleeding2 Shown to have a favorable safety and well tolerated profile2; No thrombosis observed2 In registrational program for the treatment of hemophilia B HEMOPHILIA B UNMET NEED Inco
Slide 9: SerpinPC: Designed to exploit novel pharmacology to prevent and reduce bleeding
SerpinPC: Designed to exploit novel pharmacology to prevent and reduce bleeding 9 Primary APC is the target of SerpinPC All beds Spontaneous joint bleeds • Human genetic target validation • Engineered to specifically inhibit APC • Inhibition of APC increases thrombin • Feedback loop designed to prev
Slide 10: SerpinPC Phase 2a Study: Robust and highly differentiating clinical data
10 SerpinPC Phase 2a Study Robust and highly differentiating clinical data With total exposure of over 40 patient-years across multiple dosing regimens, Phase 2a data showed a continued favorable safety and tolerability profile for SerpinPC, as well as evidence of sustained efficacy, as measured by
Slide 11: SerpinPC in registrational program for hemophilia B
11 SerpinPC In registrational program for hemophilia B, with and without inhibitors SerpinPC has not been approved by the FDA or any other regulatory authority. Granted Fast Track designation by the FDA in May 2023
Slide 12: LB101 in Solid Tumors
LB101 in Solid Tumors 12
Slide 13: LockBody: LB101 novel conditionally tetravalent PD-L1xCD47 bispecific antibody
LockBody® “It’s all about the hinge” LB101: Novel, conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody 13 Novel pharmacology focused on human IgG-derived hinges susceptible to natural intra-tumoral hinge cleavage Designed as single agent systemic treatment combining PD-L1 targeted an
Slide 14: LB101: Designed to deliver PD-L1 targeted anti-CD47 activity to the TME
LB101: Designed to optimally deliver PD-L1 targeted anti-CD47 activity to the TME 14 Tumor Unlocking: IgG1 hinges susceptible to cleavage in diseased tissue by various natural processes Peripheral Stability: IgG1 hinges naturally resistant to cleavage in serum Constitutive Fabs: PD-L1 Domains Fully
Slide 15: LB101 showed improved efficacy and durability over atezolizumab in mouse model
LB101 showed improved efficacy and durability over atezolizumab in a difficult-to-treat mouse model while being well tolerated 15 In vivo: Systemically delivered LB101 exhibited significant tumor regression In vivo: LB101 was well tolerated with no weight loss Note: MC38 hPD-L1+ syngeneic model in m
Slide 16: LB101 favorable safety and tolerability profile in non-human primates
LB101 shown to have favorable safety and tolerability profile in non- human primates up to 50 mg/kg weekly x 4 weeks 16 In-vivo: LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates • Human IgG1-like PK • No adverse observations - No anemia or thrombocytopenia - No changes in patholo
Slide 17: LB101 LockBody in Phase 1/2a Clinical Trial
17 LB101 LockBody in Phase 1/2a Clinical Trial Phase 1/2a Clinical Trial • Open-label, multicenter, dose escalation with expansion cohorts • Part 1: LB101 monotherapy in subjects with selected, advanced solid tumors; determine recommended dose(s) for expansion (Part 2) • Part 2: Design depends on Pa
Slide 18: ORX750 in Narcolepsy
ORX750 in Narcolepsy 18
Slide 19: Highly validated human target with clinical proof of concept in NT1
Highly validated human target with clinical proof of concept in NT1 Molecule design allows for potential expansion beyond NT1 19 ORX750: Orally administered, selective orexin receptor-2 (OX2R) agonist High unmet need EDS is excessive daytime sleepiness. In March 2023, ORX750 was announced as the Com
Slide 20: Structure-based drug design enabled discovery of ORX750
Structure-based drug design has enabled the discovery of ORX750 as potential orexin signaling ‘replacement therapy’ for NT1, with potential indication expansion beyond NT1 Illustration of OX2R structure bound to prototype small molecule orexin agonist (shown in purple) 20
Slide 21: ORX750 increased wakefulness in NT1 model and wild type mice
ORX750 increased wakefulness in NT1 model and wild type mice 21 NT1 model mice *P < 0.05 vs. 0 mg/kg • ORX750 increased time awake in an NT1 mouse model, showing maximal wake promotion (ceiling effect) at doses shown • Wake % time in wild type mice showed a dose- related response which supports pote
Slide 22: Centessa is fueling multiple pathways to value creation
Centessa is fueling multiple pathways to value creation 22 Multiple potential blockbuster assets Cash runway into 2026 enables clinical readouts across pipeline World-class R&D team Note: $346.2 million in cash, cash equivalents and short-term investments as of March 31, 2023.
Slide 23: Centessa Pharmaceuticals
<< CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals — Investor Presentation (June 2023) on 6ix